{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:54:22Z","timestamp":1781880862579,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00810-5","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:14:28Z","timestamp":1766150068000},"page":"279-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696798","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-0913","authenticated-orcid":false,"given":"John D.","family":"Reveille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Maldonado-Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Jing","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa Hunter","family":"Gibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05679-7","author":"MC Hwang","year":"2021","unstructured":"Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol. 2021. https:\/\/doi.org\/10.1007\/s10067-021-05679-7.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"810_CR2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"810_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"10473","key":"810_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","volume":"405","author":"V Navarro-Compan","year":"2025","unstructured":"Navarro-Compan V, Sepriano A, Capelusnik D, Baraliakos X. Axial spondyloarthritis. Lancet. 2025;405(10473):159\u201372.","journal-title":"Lancet"},{"issue":"14","key":"810_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJM197304052881403","volume":"288","author":"L Schlosstein","year":"1973","unstructured":"Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973;288(14):704\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"810_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.2003.011247","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63(5):535\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"810_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91829-5","volume":"11","author":"JT Rosenbaum","year":"2021","unstructured":"Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, et al. HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. Sci Rep. 2021;11(1):12331.","journal-title":"Sci Rep"},{"issue":"1","key":"810_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61001-w","volume":"14","author":"J Londono","year":"2024","unstructured":"Londono J, Pacheco-Tena C, Santos AM, Cardiel MH, Rodriguez-Salas G, Rueda I, et al. Differences between radiographic and non-radiographic axial spondyloarthritis patients in a Mexican cohort. Sci Rep. 2024;14(1):10342.","journal-title":"Sci Rep"},{"issue":"8","key":"810_CR9","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/rheumatology\/keab901","volume":"61","author":"D Poddubnyy","year":"2022","unstructured":"Poddubnyy D, Sieper J, Akar S, Munoz-Fernandez S, Haibel H, Hojnik M, et al. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology (Oxford). 2022;61(8):3299\u2013308.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"810_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/acr2.11555","volume":"5","author":"A Deodhar","year":"2023","unstructured":"Deodhar A, Gill T, Magrey M. Human leukocyte antigen B27-negative axial spondyloarthritis: what do we know? ACR Open Rheumatol. 2023;5(7):333\u201344.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"810_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1):e000017.","journal-title":"RMD Open"},{"issue":"10163","key":"810_CR12","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16-week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"},{"issue":"10217","key":"810_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, \u00d8stergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"issue":"2","key":"810_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"810_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"810_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13075-018-1724-7","volume":"20","author":"M Ar\u00e9valo","year":"2018","unstructured":"Ar\u00e9valo M, Gratac\u00f3s Masmitj\u00e0 J, Moreno M, Calvet J, Orellana C, Ruiz D, et al. Influence of HLA-B27 on the ankylosing spondylitis phenotype: results from the REGISPONSER database. Arthritis Res Ther. 2018;20(1):221.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"810_CR17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s10067-022-06490-8","volume":"42","author":"F Fr\u00f6hlich","year":"2023","unstructured":"Fr\u00f6hlich F, Micheroli R, Hebeisen M, Kissling S, B\u00fcrki K, Exer P, et al. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss clinical quality management registry. Clin Rheumatol. 2023;42(5):1267\u201374.","journal-title":"Clin Rheumatol"},{"key":"810_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152081","volume":"56","author":"LM \u00d8rnbjerg","year":"2022","unstructured":"\u00d8rnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindstr\u00f6m U, Askling J, et al. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Semin Arthritis Rheum. 2022;56:152081.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"810_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001846","volume":"8","author":"M Pons","year":"2022","unstructured":"Pons M, Chevret S, Briot K, d'Agostino MA, Roux C, Dougados M, et al. Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort. RMD Open. 2022;8(1):e001846. https:\/\/doi.org\/10.1136\/rmdopen-2021-001846","journal-title":"RMD Open"},{"issue":"1","key":"810_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3899\/jrheum.160958","volume":"44","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, S\u00f8rensen IJ, \u00d8stergaard M, Dreyer L, Mohamoud AA, Krogh NS, et al. Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An observational cohort study from the Nationwide DANBIO Registry. J Rheumatol. 2017;44(1):59\u201369.","journal-title":"J Rheumatol"},{"issue":"11","key":"810_CR21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-05024-w","volume":"42","author":"DI Bekele","year":"2022","unstructured":"Bekele DI, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh JA, et al. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int. 2022;42(11):1925\u201337.","journal-title":"Rheumatol Int"},{"issue":"1","key":"810_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13075-021-02650-4","volume":"23","author":"WP Maksymowych","year":"2021","unstructured":"Maksymowych WP, Kumke T, Auteri SE, Hoepken B, Bauer L, Rudwaleit M. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. Arthritis Res Ther. 2021;23(1):274.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"810_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000917","volume":"5","author":"J Sieper","year":"2019","unstructured":"Sieper J, Landew\u00e9 R, Magrey M, Anderson JK, Zhong S, Wang X, et al. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open. 2019;5(1):e000917.","journal-title":"RMD Open"},{"issue":"1","key":"810_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13075-021-02613-9","volume":"23","author":"J Braun","year":"2021","unstructured":"Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021;23(1):231.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"810_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101871","volume":"37","author":"FA van Gaalen","year":"2023","unstructured":"van Gaalen FA, Rudwaleit M. Challenges in the diagnosis of axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2023;37(3):101871.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"810_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/ard.2004.028753","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64(5):659\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"810_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003102","volume":"9","author":"J Braun","year":"2023","unstructured":"Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis. RMD Open. 2023;9(3):e003102. https:\/\/doi.org\/10.1136\/rmdopen-2023-003102","journal-title":"RMD Open"},{"issue":"2","key":"810_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.rdc.2020.01.002","volume":"46","author":"H Fahed","year":"2020","unstructured":"Fahed H, Mauro D, Ciccia F, Ziade NR. What does human leukocyte antigen B27 have to do with spondyloarthritis? Rheum Dis Clin N Am. 2020;46(2):225\u201339.","journal-title":"Rheum Dis Clin N Am"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00810-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:26Z","timestamp":1768834346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00810-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00810-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John D. Reveille has served as a consultant for Eli Lilly and Company and has received grant and\/or research support from Eli Lilly and Company. Martin Rudwaleit has served as a speaker, consultant, and\/or instructor for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma. Proton Rahman has served as a speaker and instructor for Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma, and has received grant and\/or research support from Janssen and Novartis. Jose A. Maldonado-Cocco has served as a speaker and consultant for and has received grant and\/or research support from AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, and Wyeth. Marina Magrey has served as a speaker and\/or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma. Rebecca Bolce, Khai Jing Ng, Theresa Hunter Gibble, Jeffrey Lisse, So Young Park, and Andris Kronbergs are current employees and shareholders of Eli Lilly and Company. Victoria Navarro-Comp\u00e1n has served as a speaker, consultant, and\/or instructor for AbbVie, Alfasigma, Eli Lilly and Company, Fresenius Kabi, Galapagos, Janssen, Novartis, Pfizer, and UCB Pharma, and has received grant and\/or research support from ASAS and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"COAST-V, COAST-W, and COAST-X (ClinicalTrials.gov identifiers: NCT02696785, NCT02696798, and NCT02757352, respectively) were approved by the institutional review board or ethics committee at each site and were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice Guidelines (CPMP\/ICH\/135\/95). The master ethics committee was Schulman Associates IRB (Cincinnati, OH, USA). Full listings of investigators and sites are available in previously published manuscript supplements [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ]. All patients gave written informed consent before the trials started. No additional ethical approval was sought to conduct the current post hoc analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}